Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.1-4
Ointments are usually the most effective topical formulations for treatment of mild to moderate plaque psoriasis. Foams and sprays can be applied to large areas, but many of them have an alcohol base that can cause burning in patients with sensitive skin.
...
RELEASE
Elafibranor (Iqirvo – Ipsen), a peroxisome proliferator-activated receptor (PPAR) agonist, has been granted accelerated approval by the FDA for treatment of primary biliary cholangitis (PBC) in adults. It is indicated for use in combination with ursodeoxycholic acid (ursodiol, UDCA; Urso, and others) in patients with an inadequate response to UDCA alone and as monotherapy in those unable to tolerate UDCA.
Elafibranor is the second drug to be approved for this indication. Obeticholic acid (Ocaliva), a farnesoid X receptor agonist was granted accelerated approval in 20161 and is currently under review for full approval based on the results of postmarketing studies. The FDA granted accelerated approval of seladelpar (Livdelzi), an oral PPAR-delta agonist, on August 14; it will be reviewed in a future issue.
…